Omission of sentinel lymph node biopsy in early stage luminal breast cancer: impact on adjuvant CDK4/6 inhibitor recommendation and oncological outcomes
{{output}}
Background: Sentinel lymph node biopsy (SLNB) omission is safe in many patients with small, clinically and imaging node-negative (cN0/iN0), hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative ... ...
